simvastatin has been researched along with Peritoneal Carcinomatosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asensio-Sánchez, VM; Castresana-Jauregui, I; Hernaez-Ortega, MC | 1 |
| Kang, WK; Lee, I; Lee, J; Lee, SJ; Park, C | 1 |
2 other study(ies) available for simvastatin and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
[Central retinal vein occlusion as the first symptom of ovarian cancer].
Topics: Carcinoma; Fatal Outcome; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Ovarian Neoplasms; Paraneoplastic Syndromes; Peritoneal Neoplasms; Protein S; Retinal Vein; Retinal Vein Occlusion; Simvastatin; Thrombophilia | 2013 |
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer.
Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Peritoneal Neoplasms; Simvastatin; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |